Boehringer Ingelheim announce major global strategic alliance in novel nanobody® therapeutics
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](http://www.worldpharmanews.com/images/stories/logo/boehringeringelheim.gif)
Novartis completes divestment program with transfer of Gerber baby foods business
- Details
- Category: Novartis
![Novartis AG Novartis AG](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
RotaTeq® Proves to Maintain High Clinical Efficacy Two Years Post-Vaccination in Europe
- Details
- Category: Clinical Trials
In a new analysis data in the European subgroup of the large clinical study REST (Rotavirus Efficacy and Safety Trial), the five-type rotavirus vaccine RotaTeq® demonstrated 100% clinical efficacy against severe rotavirus disease for the first rotavirus season after vaccination. The efficacy remained high through two rotavirus seasons of follow up, preventing 98% of severe rotavirus cases. This new sub-analysis was presented last week at the 25th International Congress of Paediatrics in Athens.
Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education
- Details
- Category: Pfizer
![Pfizer Pfizer](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
Study Shows IRESSA (Gefitinib) Is As Effective As Docetaxel In Pre-Treated Advanced NSCLC
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](http://www.worldpharmanews.com/images/stories/logo/astrazeneca_b.gif)
Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death
- Details
- Category: Pfizer
![Pfizer Pfizer](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
More Pharma News ...
- Novo Nordisk Appoints New Leaders of European and North American Regions
- AstraZeneca Enhances Clinical Research Capabilities in China
- European Commission Approval for biosimilar epoetin alfa
- Takeda's Investigational Compound TAK-536 Enters into Phase 2 Clinical Stage in Japan
- Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
- Strategic Acquisition of MedPointe Inc Completed
- Award for Bilobil in Poland